Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 linaclotide in children and adolescents with functional constipation
NL-OMON52398Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in functional constipation (FC) comparing Linaclotide with Placebo (2 arms). Primary endpoint: Change from baseline in 12-week spontaneous bowel movement frequency rate. Started Aug 2021; status: active, not recruiting.
02
Drugs
linaclotide
03
Conditions
functional constipation (FC)
Beyond the preview
Go deeper on NL-OMON52398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52398.